We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`

By LabMedica International staff writers
Posted on 26 Oct 2022

With few travel restrictions in place and socializing back to normal, the annual winter rise in COVID-19 cases is "poised to collide with a resurgent influenza season, causing a 'twindemic' - or even a 'tripledemic,' with a third pathogen, respiratory syncytial virus, or R. More...

S.V., in the mix. The three viruses have similar symptoms - fever, cough and congestion - but very different treatment methods, making quick identification important. Now, a new saliva-based PCR test kit can screen for the three illnesses - COVID-19, Influenza A/B and respiratory syncytial virus, or RSV – to meet the challenges of a potential "tripledemic" this winter.

The new test launched by Shield T3 (Champaign-Urbana, IL, USA), a spinout of the University of Illinois System's Discovery Partners Institute (Chicago, IL, USA), will help customers know within 24 hours if they have one of these three viruses. The Shield T3 kit, which is no bigger than a wallet, requires users to provide a small sample of drool and then mail the kit back to one of the company's CLIA-certified labs. Lab technicians run two separate tests on the sample, one for COVID, and one for flu and R.S.V.

The test kit is currently available to Shield T3 partners, including schools and companies, and also can be carried in the company's new COVID-19 vending machines, which are stocked with tests. The cost of the test is USD 70 or less, which represents significant savings over running the tests in a clinical setting. School administrators are able to access demand and positivity-rate data from the tests via an online dashboard.

"This is so much easier and less expensive than going to a campus clinic or a doctor," said David Clark, Shield T3's CEO. "We're working to become your partner for easy, rapid and accurate diagnostic tests from home, which is where you want to be if you're sick."

"Given the current state of the pandemic, when you're sick these days, you have no idea what you have; it could just be a cold, but it could be something, like COVID, that requires you to isolate," said Bill Jackson, Shield T3's principal officer. "This test gives our customers a quicker answer."

Related Links:
Shield T3
Discovery Partners Institute


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.